Dr. Jill O’Donnell-Tormey Discusses the Latest Developments in Immunological Technologies August 16, 2023August 16, 2023 CRI Staff CRI’s CEO and Director of Scientific Affairs, Dr. Jill O’Donnell-Tormey, recently spoke with ecancer about recent developments of immunological technologies that improve patient outcomes in treatment, control, and cancer prevention. Although the field has experienced significant progress in recent years, Dr. O’Donnell-Tormey says we can achieve further progress by, “…supporting excellent scientists, and giving them the resources they need to explore questions… this is where major leaps in our understanding and in the development of new drugs that are using your immune system will come from.” This content was originally published on ecancer. Read more: Post navigation Sarcomas: Unique Cancers that Merit Further Attention and Research Read Story A CRI Board Member’s Father was Diagnosed with Cancer – He Quickly Raised Over $150,000 for Research Read Story
